These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37095029)

  • 1. Corrigendum to "Taxifolin ameliorates Benzo[a]pyrene-induced lung injury possibly via stimulating the Nrf2 signalling pathway" [Int. Immunopharmacol. 96 (2021) 107566].
    Islam J; Shree A; Vafa A; Afzal SM; Sultana S
    Int Immunopharmacol; 2023 Jun; 119():110096. PubMed ID: 37095029
    [No Abstract]   [Full Text] [Related]  

  • 2. Taxifolin ameliorates Benzo[a]pyrene-induced lung injury possibly via stimulating the Nrf2 signalling pathway.
    Islam J; Shree A; Vafa A; Afzal SM; Sultana S
    Int Immunopharmacol; 2021 Jul; 96():107566. PubMed ID: 33813368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corrigendum to "Epigallocatechin gallate potentially abrogates fluoride induced lung oxidative stress, inflammation via Nrf2/Keap1 signaling pathway in rats: An in-vivo and in-silico study" [Int. Immunopharmacol. 39 (2016) 128-139].
    Shanmugam T; Selvaraj M; Poomalai S
    Int Immunopharmacol; 2020 Mar; 80():106203. PubMed ID: 31983588
    [No Abstract]   [Full Text] [Related]  

  • 4. Corrigendum to "Sophoricoside attenuates lipopolysaccharide-induced acute lung injury by activating the AMPK/Nrf2 signaling axis" [Int. Immunopharmacol. 90 (2021) 107187].
    Wu YX; Zeng S; Wan BB; Wang YY; Sun HX; Liu G; Gao ZQ; Chen D; Chen YQ; Lu MD; Pang QF
    Int Immunopharmacol; 2023 Nov; 124(Pt A):111008. PubMed ID: 37806791
    [No Abstract]   [Full Text] [Related]  

  • 5. Corrigendum to "Salidroside postconditioning attenuates ferroptosis-mediated lung ischemia-reperfusion injury by activating the Nrf2/SLC7A11 signaling axis" [Int. Immunopharmacol. 115 (2023) 109731].
    Wang Y; Chen Z; Luo J; Zhang J; Sang AM; Cheng ZS; Li XY
    Int Immunopharmacol; 2023 Apr; 117():110002. PubMed ID: 36925352
    [No Abstract]   [Full Text] [Related]  

  • 6. Corrigendum to "7-Deacetyl-gedunin suppresses proliferation of Human rheumatoid arthritis synovial fibroblast through activation of Nrf2/ARE signalling" [Int. Immunopharmacol. 107 (2022) 108557].
    Chen J; Zhu G; Sun Y; Wu Y; Wu B; Zheng W; Ma X; Zheng Y
    Int Immunopharmacol; 2023 Sep; 122():110640. PubMed ID: 37524574
    [No Abstract]   [Full Text] [Related]  

  • 7. Corrigendum to "Tanshinone IIA ameliorates the bleomycin-induced endothelial-to-mesenchymal transition via the Akt/mTOR/p70S6K pathway in a murine model of systemic sclerosis" [Int. Immunopharmacol. 77 (2019) 105968].
    Jiang Y; Hu F; Li Q; Shen C; Yang J; Li M
    Int Immunopharmacol; 2020 Jul; 84():106318. PubMed ID: 32115350
    [No Abstract]   [Full Text] [Related]  

  • 8. Corrigendum to "Ghrelin attenuates secondary brain injury following intracerebral hemorrhage by inhibiting NLRP3 inflammasome activation and promoting Nrf2/ARE signaling pathway in mice" [Int. Immunopharmacol. 79 (2020) 106180].
    Cheng Y; Chen B; Xie W; Chen Z; Yang G; Cai Y; Shang H; Zhao W
    Int Immunopharmacol; 2020 Jul; 84():106461. PubMed ID: 32278662
    [No Abstract]   [Full Text] [Related]  

  • 9. Corrigendum to "Maackiain protects against sepsis via activating AMPK/Nrf2/HO-1 pathway" [Int. Immunopharmacol. 108 (2022) 108710].
    Bai X; Zhu Y; Jie J; Li D; Song L; Luo J
    Int Immunopharmacol; 2024 Oct; 140():112877. PubMed ID: 39127491
    [No Abstract]   [Full Text] [Related]  

  • 10. Corrigendum to "Methyl helicterilate ameliorates alcohol-induced hepatic fibrosis by modulating TGF-β1/Smads pathway and mitochondria-dependent pathway" [Int. Immunopharmacol. 75 (2019) 105759].
    Wen S; Wei Y; Zhang X; Bai F; Tan S; Nie J; Wei J; Lin X
    Int Immunopharmacol; 2021 Mar; 92():107344. PubMed ID: 33418247
    [No Abstract]   [Full Text] [Related]  

  • 11. Corrigendum to "Rotundic acid ameliorates non-alcoholic steatohepatitis via SREBP-1c/SCD1 signaling pathway and modulating gut microbiota" [Int. Immunopharmacol. 99 (2021) 108065].
    Liu HJ; Cao ST; Wen BY; Han X; Li Y; Li S; Li J; Zhang L
    Int Immunopharmacol; 2023 Dec; 125(Pt A):111084. PubMed ID: 37879973
    [No Abstract]   [Full Text] [Related]  

  • 12. Corrigendum to "Emodin ameliorates ulcerative colitis by the flagellin-TLR5 dependent pathway in mice" [Int. Immunopharmacol. 59 (2018) 269-275].
    Luo S; Deng X; Liu Q; Pan Z; Zhao Z; Zhou L; Luo X
    Int Immunopharmacol; 2018 Sep; 62():337. PubMed ID: 29983242
    [No Abstract]   [Full Text] [Related]  

  • 13. Corrigendum to "Baccatin III ameliorates bleomycin-induced pulmonary fibrosis via suppressing TGF-β1 production and TGF-β1-induced fibroblasts differentiation" [Int Immunopharmacol. 74 (2019) 105696].
    Nie Y; Zhang D; Qian F; Wu Y
    Int Immunopharmacol; 2022 Mar; 104():108496. PubMed ID: 35016851
    [No Abstract]   [Full Text] [Related]  

  • 14. Corrigendum to "Sivelestat ameliorates sepsis-induced myocardial dysfunction by activating the PI3K/AKT/mTOR signaling pathway" [Int. Immunopharmacol. 128 (2024) https://doi.org/10.1016/j.intimp.2023.111466].
    Geng H; Zhang H; Cheng L; Dong S
    Int Immunopharmacol; 2024 Apr; 131():111873. PubMed ID: 38514302
    [No Abstract]   [Full Text] [Related]  

  • 15. Corrigendum to "4-Hydroxybenzo[d]oxazol-2(3H)-one ameliorates LPS/D-GalN-induced acute liver injury by inhibiting TLR4/NF-κB and MAPK signaling pathways in mice" [Int. Immunopharmacol. 83 (2020) 106445].
    Wang H; Wei X; Wei X; Sun X; Huang X; Liang Y; Xu W; Zhu X; Lin X; Lin J
    Int Immunopharmacol; 2020 Sep; 86():106722. PubMed ID: 32593975
    [No Abstract]   [Full Text] [Related]  

  • 16. Retraction notice to "Corrigendum to "MLL1 promotes migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis by activating the TRIF/NF-κB signaling pathway via H3K4me3 enrichment in the TLR4 promoter region"" [Int. Immunopharmacol. 82 (2020) 106220] [Int. Immunopharmacol. 92 (2021) 107321].
    Zhang Y; Ji T; Ma S; Wu W
    Int Immunopharmacol; 2023 Apr; 117():109865. PubMed ID: 36822094
    [No Abstract]   [Full Text] [Related]  

  • 17. Corrigendum to "mTOR aggravated CD4
    Zhao G; Xie Y; Lei X; Guo R; Cui N
    Int Immunopharmacol; 2024 Dec; 143(Pt 1):113389. PubMed ID: 39406572
    [No Abstract]   [Full Text] [Related]  

  • 18. Corrigendum to "Gypsophila elegans isoorientin-2″-O-α-L-arabinopyranosyl ameliorates porcine serum-induced immune liver fibrosis by inhibiting NF-κB signaling pathway and suppressing HSC activation" [Int. Immunopharmacol. 54 (2018) 60-67].
    Bai F; Huang Q; Wei J; Lv S; Chen Y; Liang C; Wei L; Lu Z; Lin X
    Int Immunopharmacol; 2023 Sep; 122():110697. PubMed ID: 37500383
    [No Abstract]   [Full Text] [Related]  

  • 19. Corrigendum to "Zerumbone enhances the Th1 response and ameliorates ovalbumin-induced Th2 responses and airway inflammation in mice" [Int. Immunopharmacol. 24 (2015) 383-391].
    Shieh YH; Huang HM; Ching-Chiung Wang ; Lee CC; Fan CK; Lee YL
    Int Immunopharmacol; 2017 Sep; 50():371. PubMed ID: 28751107
    [No Abstract]   [Full Text] [Related]  

  • 20. Corrigendum to "Dioscin reduces lipopolysaccharide-induced inflammatory liver injury via regulating TLR4/MyD88 signal pathway" [Int. Immunopharmacol. 36 (2016) 132-141].
    Yao H; Hu C; Yin L; Tao X; Xu L; Qi Y; Han X; Xu Y; Zhao Y; Wang C; Peng J
    Int Immunopharmacol; 2019 Sep; 74():105786. PubMed ID: 31402320
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.